{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T08:08:59Z","timestamp":1788768539922,"version":"build-2803163510"},"reference-count":96,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Mycosis fungoides (MF) and S\u00e9zary syndrome (SS) are the most prevalent subtypes of cutaneous T-cell lymphoma (CTCL). Systemic therapies span multiple drug classes, and as most are administered with palliative intent over prolonged periods, the adverse event (AE) profile of each agent is as clinically important as its efficacy. No comprehensive narrative review has synthesized AE data across all National Comprehensive Cancer Network (NCCN)-recommended systemic therapies for MF\/SS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To summarize and compare the AE profiles of all 14 NCCN guideline-recommended systemic therapies for MF and SS, with emphasis on cutaneous toxicities and their distinction from active disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Systemic therapies were identified from Version 2.2026 NCCN Guidelines for Cutaneous Lymphomas. Safety data were abstracted from available Phase II and III trials supporting guideline inclusion, with attention to AE frequency, severity, dose-limiting toxicities, and treatment discontinuation rates. PubMed and Scopus were searched for case reports and series capturing rare or delayed toxicities not represented in prospective trials. Data were narratively synthesized given heterogeneity across study designs and reporting practices.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Fourteen NCCN-recommended systemic agents were reviewed, spanning antibody-drug conjugates, monoclonal antibodies, histone deacetylase (HDAC) inhibitors, retinoids, antifolates, immunotoxins, cytotoxic chemotherapies, interferons, and immune checkpoint inhibitors. Toxicity profiles varied substantially by drug class. Peripheral neuropathy was the defining AE of brentuximab vedotin. Mogamulizumab was distinguished by mogamulizumab-associated rash, a treatment-emergent immune reaction that closely mimics CTCL progression. Bexarotene required proactive management of hypertriglyceridemia and central hypothyroidism. HDAC inhibitors carried gastrointestinal, hematologic, and cardiac risks, while cytotoxic agents posed variable risks of myelosuppression, mucositis, and hepatotoxicity. Immunomodulatory agents introduced risks of opportunistic infection and paradoxical disease flares.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Systemic therapies for MF\/SS carry distinct AE profiles that should inform treatment selection, patient counseling, and monitoring. A recurring challenge is distinguishing cutaneous drug toxicity from CTCL progression, underscoring the importance of therapy-specific toxicity awareness. Standardized AE reporting and patient-centered outcome measures are needed to optimize long-term care in this population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1912209","type":"journal-article","created":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T07:32:26Z","timestamp":1788766346000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Adverse events associated with systemic cutaneous T-cell lymphoma therapies: a narrative review"],"prefix":"10.3389","volume":"13","author":[{"given":"Krithika","family":"Nayudu","sequence":"first","affiliation":[{"name":"Medical College of Georgia","place":["Augusta, GA, United States"]},{"name":"Center for Cutaneous Oncology, Dana Farber Cancer Institute","place":["Boston, MA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrix B.","family":"Thompson","sequence":"additional","affiliation":[{"name":"Center for Cutaneous Oncology, Dana Farber Cancer Institute","place":["Boston, MA, United States"]},{"name":"Harvard Medical School","place":["Boston, MA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Larocca","sequence":"additional","affiliation":[{"name":"Center for Cutaneous Oncology, Dana Farber Cancer Institute","place":["Boston, MA, United States"]},{"name":"Harvard Medical School","place":["Boston, MA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"3768","DOI":"10.1182\/blood-2004-09-3502","article-title":"WHO-EORTC classification for cutaneous lymphomas","volume":"105","author":"Willemze","year":"2005","journal-title":"Blood"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1182\/blood-2007-03-055749","article-title":"Revisions to the staging and classification of mycosis fungoides and sezary syndrome: a proposal of the international society for cutaneous lymphomas (ISCL) and the cutaneous lymphoma task force of the European organization of research and treatment of cancer (EORTC)","volume":"110","author":"Olsen","year":"2007","journal-title":"Blood"},{"key":"B3","volume-title":"National Comprehensive Cancer Network","year":"2026"},{"key":"B4","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1111\/bjd.17941","article-title":"Health-related quality of life and economic implications of cutaneous T-cell lymphoma","volume":"182","author":"Semenov","year":"2020","journal-title":"Br J Dermatol"},{"key":"B5","year":"2025"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1200\/JCO-24-01549","article-title":"Efficacy and safety of denileukin diftitox-cxdl, an improved purity formulation of denileukin diftitox, in patients with relapsed or refractory cutaneous T-cell lymphoma","volume":"43","author":"Foss","year":"2025","journal-title":"JCO"},{"key":"B7","doi-asserted-by":"publisher","first-page":"51","DOI":"10.3816\/CLM.2006.n.039","article-title":"Phase II evaluation of gemcitabine monotherapy for cutaneous T-cell lymphoma","volume":"7","author":"Duvic","year":"2006","journal-title":"Clin Lymphoma Myeloma"},{"key":"B8","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1002\/cncr.21449","article-title":"Gemcitabine as frontline treatment for cutaneous T-cell lymphoma: phase II study of 32 patients","volume":"104","author":"Marchi","year":"2005","journal-title":"Cancer"},{"key":"B9","doi-asserted-by":"publisher","first-page":"4091","DOI":"10.1200\/JCO.2011.39.8065","article-title":"Prospective international multicenter phase II trial of intravenous pegylated liposomal doxorubicin monochemotherapy in patients with stage IIB, IVA, or IVB advanced mycosis fungoides: final results from EORTC 21012","volume":"30","author":"Dummer","year":"2012","journal-title":"J Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/s0190-9622(89)70049-9","article-title":"Interferon alfa-2a in the treatment of cutaneous T cell lymphoma","volume":"20","author":"Olsen","year":"1989","journal-title":"J Am Acad Dermatol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1093\/jnci\/82.3.208","article-title":"Phase II study of recombinant human interferon gamma for treatment of cutaneous T-cell lymphoma","volume":"82","author":"Kaplan","year":"1990","journal-title":"J Natl Cancer Inst"},{"key":"B12","doi-asserted-by":"publisher","first-page":"4267","DOI":"10.1182\/blood-2002-09-2802","article-title":"Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides\/sezary syndrome","volume":"101","author":"Lundin","year":"2003","journal-title":"Blood"},{"key":"B13","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1200\/JCO.19.01056","article-title":"Pembrolizumab in relapsed and refractory mycosis fungoides and s\u00e9zary syndrome: a multicenter phase II study","volume":"38","author":"Khodadoust","year":"2020","journal-title":"JCO"},{"key":"B14","doi-asserted-by":"publisher","first-page":"5748","DOI":"10.1158\/1078-0432.CCR-11-0556","article-title":"Multicenter phase II trial of temozolomide in mycosis fungoides\/sezary syndrome: correlation with O6-methylguanine-DNA methyltransferase and mismatch repair proteins","volume":"17","author":"Querfeld","year":"2011","journal-title":"Clin Cancer Res"},{"key":"B15","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/S0140-6736(17)31266-7","article-title":"Brentuximab vedotin or physician\u2019s choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial","volume":"390","author":"Prince","year":"2017","journal-title":"Lancet"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1016\/S1470-2045(18)30379-6","article-title":"Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial","volume":"19","author":"Kim","year":"2018","journal-title":"Lancet Oncol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"3552","DOI":"10.1158\/1078-0432.CCR-16-2064","article-title":"Results from a phase I\/II open-label, dose-finding study of pralatrexate and oral bexarotene in patients with relapsed\/refractory cutaneous T-cell lymphoma","volume":"23","author":"Duvic","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B18","doi-asserted-by":"publisher","first-page":"4485","DOI":"10.1200\/JCO.2010.28.9066","article-title":"Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma","volume":"28","author":"Whittaker","year":"2010","journal-title":"J Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.1200\/JCO.2006.10.2434","article-title":"Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma","volume":"25","author":"Olsen","year":"2007","journal-title":"J Clin Oncol"},{"key":"B20","first-page":"581","article-title":"Phase 2 and 3 clinical trial of oral bexarotene (targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma","volume":"137","author":"Duvic","year":"2001","journal-title":"Arch Dermatol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","article-title":"Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory hodgkin\u2019s lymphoma","volume":"30","author":"Younes","year":"2012","journal-title":"J Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1200\/JCO.2011.38.0402","article-title":"Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study","volume":"30","author":"Pro","year":"2012","journal-title":"J Clin Oncol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"3750","DOI":"10.1200\/JCO.2014.60.3969","article-title":"Phase II investigator-initiated study of brentuximab vedotin in mycosis fungoides and s\u00e9zary syndrome with Variable CD30 expression level: a multi-institution collaborative project","volume":"33","author":"Kim","year":"2015","journal-title":"J Clin Oncol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.jdcr.2021.12.032","article-title":"Brentuximab-induced hand-foot syndrome in a patient with cutaneous T-cell lymphoma","volume":"21","author":"Shaposhnik","year":"2022","journal-title":"JAAD Case Rep"},{"key":"B25","doi-asserted-by":"publisher","first-page":"3883","DOI":"10.1111\/bcp.15247","article-title":"Brentuximab-induced splinter nail haemorrhages in a patient with s\u00e9zary syndrome: a case report","volume":"88","author":"Filipovic","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"adv41982","DOI":"10.2340\/actadv.v104.41982","article-title":"Brentuximab vedotin-induced tumour lysis syndrome in mycosis fungoides: a case report","volume":"104","author":"Olszewska","year":"2024","journal-title":"Acta Derm Venereol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1111\/bjd.17533","article-title":"New therapies and old side-effects in mycosis fungoides treatment: brentuximab vedotin-induced alopecia","volume":"180","author":"Pileri","year":"2019","journal-title":"Br J Dermatol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1610445","DOI":"10.3389\/pore.2022.1610445","article-title":"Case report: brentuximab vedotin associated acute pancreatitis in a pediatric hodgkin lymphoma patient: case report and literature review","volume":"28","author":"Truszkowska","year":"2022","journal-title":"Pathol Oncol Res"},{"key":"B29","doi-asserted-by":"publisher","first-page":"3029","DOI":"10.1097\/MS9.0000000000001878","article-title":"Brentuximab-induced pneumonitis and organizing pneumonia: a case report with literiture review","volume":"86","author":"Khalil","year":"2024","journal-title":"Ann Med Surg (Lond)"},{"key":"B30","doi-asserted-by":"publisher","first-page":"e5138","DOI":"10.7759\/cureus.5138","article-title":"Hypertriglyceridemia induced pancreatitis due to brentuximab therapy: first case report","volume":"11","author":"Maradana","year":"2019","journal-title":"Cureus"},{"key":"B31","doi-asserted-by":"publisher","first-page":"206","DOI":"10.11406\/rinketsu.63.206","article-title":"Progressive multifocal leukoencephalopathy during the treatment for mycosis fungoides","volume":"63","author":"Sawayama","year":"2022","journal-title":"Rinsho Ketsueki"},{"key":"B32","doi-asserted-by":"publisher","first-page":"e251867","DOI":"10.1136\/bcr-2022-251867","article-title":"Severe insulin resistance in a patient with diabetes after treatment with brentuximab vedotin","volume":"17","author":"Peeters","year":"2024","journal-title":"BMJ Case Rep"},{"key":"B33","doi-asserted-by":"publisher","first-page":"883","DOI":"10.6004\/jadpro.2019.10.8.10","article-title":"Mogamulizumab-kpkc: a novel therapy for the treatment of cutaneous T-cell lymphoma","volume":"10","author":"Watson","year":"2019","journal-title":"J Adv Pract Oncol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1001\/jamadermatol.2021.0877","article-title":"Clinical characterization of mogamulizumab-associated rash during treatment of mycosis fungoides or s\u00e9zary syndrome","volume":"157","author":"Hirotsu","year":"2021","journal-title":"JAMA Dermatol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"e191","DOI":"10.1111\/ajd.14022","article-title":"Mogamulizumab-associated rash: a challenging case report and literature review","volume":"64","author":"Mart\u00ednez-Fern\u00e1ndez","year":"2023","journal-title":"Australas J Dermatol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1111\/ddg.15432","article-title":"Mogamulizumab-associated rash\u2014case series and review of the literature","volume":"22","author":"Hansen","year":"2024","journal-title":"J Dtsch Dermatol Ges"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1111\/ddg.15816","article-title":"Acneiform type of mogamulizumab-associated rash","volume":"23","author":"Hansen-Abeck","year":"2025","journal-title":"J Dtsch Dermatol Ges"},{"key":"B38","doi-asserted-by":"publisher","first-page":"adv00158","DOI":"10.2340\/00015555-3527","article-title":"Mogamulizumab-induced mucocutaneous lichenoid reaction: a case report and short review","volume":"100","author":"Trager","year":"2020","journal-title":"Acta Derm Venereol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.jdcr.2020.12.035","article-title":"Mogamulizumab-induced interface dermatitis drug rash treated successfully with methotrexate and extracorporeal photopheresis in a patient with s\u00e9zary syndrome","volume":"9","author":"Breen","year":"2021","journal-title":"JAAD Case Rep"},{"key":"B40","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.jdcr.2023.08.044","article-title":"Alopecia areata-like presentations with mogamulizumab therapy","volume":"41","author":"Kincaid","year":"2023","journal-title":"JAAD Case Rep"},{"key":"B41","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s00105-024-05349-0","article-title":"Mogamulizumab-associated rash: cutaneous T-cell lymphoma in complete remission","volume":"75","author":"Leonhardt","year":"2024","journal-title":"Dermatol (Heidelb)"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1016\/j.jaad.2023.05.082","article-title":"Prevalence and implications of mogamulizumab-induced immune-related adverse events in mycosis fungoides\/s\u00e9zary syndrome; a single-center experience","volume":"89","author":"Jfri","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"e694","DOI":"10.1093\/oncolo\/oyad155","article-title":"Mogamulizumab-associated myositis with and without myasthenia Gravis and\/or myocarditis in patients with T-cell lymphoma","volume":"28","author":"Virgen","year":"2023","journal-title":"Oncologist"},{"key":"B44","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.jdcr.2021.10.034","article-title":"Alopecia areata after mogamulizumab treatment","volume":"19","author":"Raval","year":"2022","journal-title":"JAAD Case Rep"},{"key":"B45","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1684\/ejd.2021.4179","article-title":"Scarring alopecia developing after mogamulizumab-associated rash","volume":"31","author":"Raval","year":"2021","journal-title":"Eur J Dermatol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1684\/ejd.2021.4002","article-title":"Mogamulizumab-induced vitiligo in patients with s\u00e9zary syndrome: three cases","volume":"31","author":"Algarni","year":"2021","journal-title":"Eur J Dermatol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"e488","DOI":"10.1111\/ijd.16102","article-title":"Two cases of generalized eruptive lentiginosis in cutaneous T-cell lymphoma following mogamulizumab treatment","volume":"61","author":"Vico-Alonso","year":"2022","journal-title":"Int J Dermatol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"470","DOI":"10.23736\/S2784-8671.24.07953-2","article-title":"Mogamulizumab associated crusted scabies: a rare diagnostic confounder","volume":"159","author":"Giunipero DI Corteranzo","year":"2024","journal-title":"Ital J Dermatol Venerol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.jdcr.2024.09.021","article-title":"Potential mogamulizumab-associated inflammatory bowel disease in cutaneous T-cell lymphoma management","volume":"54","author":"Blanchard","year":"2024","journal-title":"JAAD Case Rep"},{"key":"B50","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1684\/ejd.2024.4744","article-title":"Mogamulizumab for s\u00e9zary syndrome: long-term remission with associated autoimmune haemolytic anaemia","volume":"34","author":"L\u00e9","year":"2024","journal-title":"Eur J Dermatol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.jdcr.2026.01.046","article-title":"Mogamulizumab-associated lymphadenopathy masquerading as lymphoma progression","volume":"70","author":"Tizro","year":"2026","journal-title":"JAAD Case Rep"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1733473","DOI":"10.3389\/fcimb.2026.1733473","article-title":"BK polyomavirus-associated progressive multifocal leukoencephalopathy following mogamulizumab therapy for erythrodermic mycosis fungoides","volume":"16","author":"Longo","year":"2026","journal-title":"Front Cell Infect Microbiol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1200\/JCO.2010.29.9024","article-title":"Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study","volume":"29","author":"O'Connor","year":"2011","journal-title":"J Clin Oncol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"295","DOI":"10.5114\/ada.2021.106206","article-title":"Efficacy, quality of life, and safety of methotrexate versus interferon in head-to-head treatment in advanced stages of mycosis fungoides and sezary syndrome. Prospective trial (NCT02323659)","volume":"38","author":"Chmielowska","year":"2021","journal-title":"Postepy Dermatol Alergol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/s0190-9622(96)80062-4","article-title":"Low-dose methotrexate to treat erythrodermic cutaneous T-cell lymphoma: results in twenty-nine patients","volume":"34","author":"Zackheim","year":"1996","journal-title":"J Am Acad Dermatol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/s0190-9622(03)01591-3","article-title":"Low-dose methotrexate to treat mycosis fungoides: a retrospective study in 69 patients","volume":"49","author":"Zackheim","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.2147\/CCID.S419534","article-title":"Cutaneous methotrexate-related epstein\u2013barr virus-positive diffuse large B-cell lymphoma in a patient with granulomatous cutaneous T-cell lymphoma: a case report and literature review","volume":"16","author":"Kositkuljorn","year":"2023","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1001\/jamadermatol.2017.6062","article-title":"Methotrexate-associated B-cell lymphoproliferative disease in a patient with cutaneous T-cell lymphoma","volume":"154","author":"Maderal","year":"2018","journal-title":"JAMA Dermatol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1093\/clinids\/17.4.776","article-title":"Cutaneous cryptococcosis in a patient with cutaneous T cell lymphoma receiving therapy with photopheresis and methotrexate","volume":"17","author":"Frieden","year":"1993","journal-title":"Clin Infect Dis"},{"key":"B60","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.2147\/tcrm.s1155","article-title":"Methotrexate-induced cutaneous ulceration in patients with erythrodermic mycosis fungoides","volume":"4","author":"Breneman","year":"2008","journal-title":"Ther Clin Risk Manag"},{"key":"B61","doi-asserted-by":"publisher","first-page":"5410","DOI":"10.1200\/JCO.2008.21.6150","article-title":"Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma","volume":"27","author":"Piekarz","year":"2009","journal-title":"J Clin Oncol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.jdcr.2016.05.013","article-title":"Romidepsin-induced neutrophilic urticaria","volume":"2","author":"Scott","year":"2016","journal-title":"JAAD Case Rep"},{"key":"B63","doi-asserted-by":"publisher","first-page":"412","DOI":"10.3816\/CLM.2009.n.082","article-title":"Evaluation of the long-term tolerability and clinical benefit of vorinostat in patients with advanced cutaneous T-cell lymphoma","volume":"9","author":"Duvic","year":"2009","journal-title":"Clin Lymphoma Myeloma"},{"key":"B64","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1182\/blood-2006-06-025999","article-title":"Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)","volume":"109","author":"Duvic","year":"2007","journal-title":"Blood"},{"key":"B65","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1200\/JCO.2001.19.9.2456","article-title":"Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results","volume":"19","author":"Duvic","year":"2001","journal-title":"J Clin Oncol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.medcli.2015.07.017","article-title":"Thyroid and lipidic dysfunction associated with bexarotene in cutaneous T-cell lymphoma","volume":"146","author":"Rodriguez Suarez","year":"2016","journal-title":"Med Clin (Barc)"},{"key":"B67","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1007\/s11102-013-0523-z","article-title":"Reversible pituitary insufficiency due to bexarotene therapy in a patient with mycosis fungoides","volume":"17","author":"Atmaca","year":"2014","journal-title":"Pituitary"},{"key":"B68","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1111\/j.1468-3083.2007.02341.x","article-title":"Acute hyperkeratotic and desquamative reaction in a patient with s\u00e9zary syndrome treated with bexarotene","volume":"22","author":"Bagazgoitia","year":"2008","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B69","first-page":"1014","article-title":"Development of hodgkin\u2019s lymphoma under bexarotene treatment for s\u00e9zary syndrome and review of the literature","volume":"9","author":"Sanli","year":"2010","journal-title":"J Drugs Dermatol"},{"key":"B70","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/j.jaad.2005.02.055","article-title":"Bexarotene treatment of late-stage mycosis fungoides and s\u00e9zary syndrome: development of extracutaneous lymphoma in 6 patients","volume":"52","author":"Bouwhuis","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"B71","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1586\/14737140.5.1.33","article-title":"Denileukin diftitox: a concise clinical review","volume":"5","author":"Eklund","year":"2005","journal-title":"Expert Rev Anticancer Ther"},{"key":"B72","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1002\/ajh.21180","article-title":"Lethal vascular leak syndrome after denileukin diftitox administration to a patient with cutaneous gamma\/delta T-cell lymphoma and occult cirrhosis","volume":"83","author":"Avarbock","year":"2008","journal-title":"Am J Hematol"},{"key":"B73","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1007\/s00277-014-2121-1","article-title":"Long-term outcome of patients with advanced-stage cutaneous T cell lymphoma treated with gemcitabine","volume":"93","author":"Pellegrini","year":"2014","journal-title":"Ann Hematol"},{"key":"B74","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1111\/j.1365-2133.2009.09230.x","article-title":"Gemcitabine treatment in cutaneous T-cell lymphoma: a multicentre study of 23 cases","volume":"161","author":"Jidar","year":"2009","journal-title":"Br J Dermatol"},{"key":"B75","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1345\/aph.10268","article-title":"Linear immunoglobulin a bullous dermatosis induced by gemcitabine","volume":"35","author":"Del Pozo","year":"2001","journal-title":"Ann Pharmacother"},{"key":"B76","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1097\/00001813-200309000-00012","article-title":"Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis in a patient receiving concurrent radiation and gemcitabine","volume":"14","author":"Sommers","year":"2003","journal-title":"Anti-Cancer Drugs"},{"key":"B77","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1093\/bjd\/ljad311","article-title":"Efficacy of single-agent chemotherapy with pegylated liposomal doxorubicin or gemcitabine in a diverse cohort of patients with recalcitrant cutaneous T-cell lymphoma","volume":"190","author":"Weiner","year":"2024","journal-title":"Br J Dermatol"},{"key":"B78","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1001\/archderm.144.6.727","article-title":"Prospective multicenter study of pegylated liposomal doxorubicin treatment in patients with advanced or refractory mycosis fungoides or s\u00e9zary syndrome","volume":"144","author":"Quereux","year":"2008","journal-title":"Arch Dermatol"},{"key":"B79","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1111\/ced.15224","article-title":"Real-life experience of using pegylated liposomal doxorubicin in primary cutaneous T-cell lymphomas","volume":"47","author":"Falkenhain-L\u00f3pez","year":"2022","journal-title":"Clin Experimental Derm"},{"key":"B80","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1001\/jamadermatol.2026.0042","article-title":"Preventing hand-foot syndrome in patients with cancer: a systematic review and network meta-analysis","volume":"162","author":"Baskarane","year":"2026","journal-title":"JAMA Dermatol"},{"key":"B81","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1111\/j.1600-0609.2005.00497.x","article-title":"Long-term experience with low-dose interferon-\u03b1 and PUVA in the management of early mycosis fungoides","volume":"75","author":"Rupoli","year":"2005","journal-title":"Eur J Haematol"},{"key":"B82","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1093\/jnci\/82.3.203","article-title":"Interferon alfa-2a combined with phototherapy in the treatment of cutaneous T-cell lymphoma","volume":"82","author":"Kuzel","year":"1990","journal-title":"J Natl Cancer Inst"},{"key":"B83","doi-asserted-by":"publisher","first-page":"306","DOI":"10.5414\/CP204003","article-title":"Interferon \u03b1-induced lupus-like reaction in a mycosis fungoides patient: a case report","volume":"60","author":"Fatemi Naeini","year":"2022","journal-title":"Int J Clin Pharmacol Ther"},{"key":"B84","doi-asserted-by":"publisher","first-page":"784","DOI":"10.3324\/haematol.11127","article-title":"Low-dose intermittent alemtuzumab in the treatment of s\u00e9zary syndrome: clinical and immunologic findings in 14 patients","volume":"92","author":"Bernengo","year":"2007","journal-title":"Haematologica"},{"key":"B85","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1111\/cup.12800","article-title":"Histopathologic spectrum of hypersensitivity reactions associated with anti-CD52 therapy (alemtuzumab)","volume":"43","author":"Clark","year":"2016","journal-title":"J Cutan Pathol"},{"key":"B86","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1034\/j.1600-0609.2003.00143.x","article-title":"Treatment of patients with advanced mycosis fungoides and s\u00e9zary syndrome with alemtuzumab","volume":"71","author":"Kennedy","year":"2003","journal-title":"Eur J Haematol"},{"key":"B87","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1016\/S1470-2045(09)70265-7","article-title":"Management of T-cell and natural-killer-cell neoplasms in Asia: consensus statement from the Asian oncology summit 2009","volume":"10","author":"Kwong","year":"2009","journal-title":"Lancet Oncol"},{"key":"B88","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1182\/blood-2008-02-138800","article-title":"EBV-positive immunodeficiency lymphoma after alemtuzumab-CHOP therapy for peripheral T-cell lymphoma","volume":"112","author":"Kluin-Nelemans","year":"2008","journal-title":"Blood"},{"key":"B89","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1111\/bjd.12690","article-title":"Long-term efficacy and safety of alemtuzumab in advanced primary cutaneous T-cell lymphomas","volume":"170","author":"de Masson","year":"2014","journal-title":"Br J Dermatol"},{"key":"B90","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.3109\/10428190903216770","article-title":"Alemtuzumab for relapsed and refractory erythrodermic cutaneous T-cell lymphoma: a single institution experience from the Robert H. Lurie comprehensive cancer center","volume":"50","author":"Querfeld","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"B91","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1097\/DAD.0000000000000156","article-title":"Transformation of s\u00e9zary syndrome into CD30\u2009+\u2009anaplastic large T-cell lymphoma after alemtuzumab therapy with evidence of clonal unity","volume":"37","author":"Nevet","year":"2015","journal-title":"Am J Dermatopathol"},{"key":"B92","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1001\/archdermatol.2012.2089","article-title":"Differential expression of programmed death-1 (PD-1) in s\u00e9zary syndrome and mycosis fungoides","volume":"148","author":"\u00c7etin\u00f6zman","year":"2012","journal-title":"Arch Dermatol"},{"key":"B93","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1001\/jamadermatol.2025.0251","article-title":"Pembrolizumab in relapsed or refractory mycosis fungoides or s\u00e9zary syndrome","volume":"161","author":"Elghawy","year":"2025","journal-title":"JAMA Dermatol"},{"key":"B94","doi-asserted-by":"publisher","first-page":"e164793","DOI":"10.1172\/jci.insight.164793","article-title":"Hyperprogression of cutaneous T cell lymphoma after anti-PD-1 treatment","volume":"8","author":"Gao","year":"2023","journal-title":"JCI Insight"},{"key":"B95","first-page":"1283","article-title":"Phase II trial of temozolomide in patients with pretreated cutaneous T-cell lymphoma","volume":"90","author":"Tani","year":"2005","journal-title":"Haematologica"},{"key":"B96","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1002\/ajh.27735","article-title":"Mycosis fungoides, s\u00e9zary syndrome, and cutaneous B-cell lymphomas: 2025 update on diagnosis, risk-stratification, and management","volume":"100","author":"Hristov","year":"2025","journal-title":"Am J Hematol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1912209\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T07:32:28Z","timestamp":1788766348000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1912209\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,7]]},"references-count":96,"alternative-id":["10.3389\/fmed.2026.1912209"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1912209","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,7]]},"article-number":"1912209"}}